Shilpa Medicare update on USFDA inspection of Polepally formulations unit
Capital Market Shilpa Medicare announced that the US FDA intimated the Company that based on its inspection from 11 November to 30 November 2017, the Unit of the Company located at S-20 TO S-24/A, Pharmaceutical Formulations SEZ TSIIC, Green Industrial Park, Polepally, Jadcherla, Mahabubnagar, Telangana, India, has been determined that the inspection classification of this facility is VAI.
The is a confirmation that earlier status of our formulation Unit is maintained.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
